Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Sourij, C; Tripolt, NJ; Aziz, F; Aberer, F; Forstner, P; Obermayer, AM; Kojzar, H; Kleinhappl, B; Pferschy, PN; Mader, JK; Cvirn, G; Goswami, N; Wachsmuth, N; Eckstein, ML; Müller, A; Abbas, F; Lenz, J; Steinberger, M; Knoll, L; Krause, R; Stradner, M; Schlenke, P; Sareban, N; Prietl, B; Kaser, S; Moser, O; Steinmetz, I; Sourij, H, , COVAC-DM, study, group.
Humoral immune response to COVID-19 vaccination in diabetes is age-dependent but independent of type of diabetes and glycaemic control: The prospective COVAC-DM cohort study.
Diabetes Obes Metab. 2022; 24(5):849-858 Doi: 10.1111/dom.14643 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Führende Autor*innen der Med Uni Graz
Sourij Caren
Sourij Harald
Tripolt Norbert
Co-Autor*innen der Med Uni Graz
Abbas Farah
Aberer Felix
Aziz Faisal
Cvirn Gerhard
Eckstein Max Lennart
Forstner Patrick
Goswami Nandu
Kleinhappl Barbara
Knoll Lisa
Kojzar Harald
Krause Robert
Lenz Jacqueline
Mader Julia
Moser Othmar
Müller Alexander
Obermayer Anna Maria Antonia
Pferschy Peter
Prietl Barbara
Sareban Nazanin
Schlenke Peter
Steinmetz Ivo
Stradner Martin Helmut

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

AIMS: To investigate the seroconversion following first and second COVID-19 vaccination in people with type 1 and type 2 diabetes in relation to glycaemic control prior to vaccination and to analyse the response in comparison to individuals without diabetes. MATERIALS AND METHODS: This prospective, multicentre cohort study analysed people with type 1 and type 2 diabetes and a glycated haemoglobin level ≤58 mmol/mol (7.5%) or >58 mmol/mol (7.5%), respectively, and healthy controls. Roche's Elecsys anti-SARS-CoV-2 S immunoassay targeting the receptor-binding domain was used to quantify anti-spike protein antibodies 7 to 14 days after the first and 14 to 21 days after the second vaccination. RESULTS: A total of 86 healthy controls were enrolled in the study, as well as 161 participants with diabetes, of whom 150 (75 with type 1 diabetes and 75 with type 2 diabetes) were eligible for the analysis. After the first vaccination, only 52.7% of participants in the type 1 diabetes group and 48.0% of those in the type 2 diabetes group showed antibody levels above the cut-off for positivity. Antibody levels after the second vaccination were similar in participants with type 1 diabetes, participants with type 2 diabetes and healthy controls after adjusting for age, sex and multiple testing (P > 0.05). Age (r = -0.45, P < 0.001) and glomerular filtration rate (r = 0.28, P = 0.001) were significantly associated with antibody response. CONCLUSIONS: Anti-SARS-CoV-2 S receptor-binding domain antibody levels after the second vaccination were comparable in healthy controls and in participants with type 1 and type 2 diabetes, irrespective of glycaemic control. Age and renal function correlated significantly with the extent of antibody levels.
Find related publications in this database (using NLM MeSH Indexing)
COVID-19 - prevention & control
COVID-19 Vaccines - therapeutic use
Cohort Studies - administration & dosage
Diabetes Mellitus, Type 2 - complications
Humans - administration & dosage
Immunity, Humoral - administration & dosage
Prospective Studies - administration & dosage
Vaccination - administration & dosage

Find related publications in this database (Keywords)
observational study
type 1 diabetes
type 2 diabetes
© Med Uni Graz Impressum